Kategorie: Forschung

Prilenia erreicht letzten Patientenbesuch in klinischer Phase-3-Studie PROOF-HD zur Huntington-Krankheit

PROOF-HD is the only late-stage study in Huntington’s disease targeting clinical progression; topline results expected in early Q2 2023 NAARDEN, Netherlands and WALTHAM, Mass., 28 March 2023 – Prilenia Therapeutics B.V., a […]

Neues von Roche/Genentech zur GENERATION HD2-Studie

Roche/ Genentech announce that Phase II GENERATION HD2 study is now open. This is great news for the international community since it is planned to run in 15 countries (Argentina, […]

Novartis beendet die VIBRANT-HD-Studie

Novartis shared today the difficult news that they are stopping the VIBRANT-HD study of Branaplam, after some participants devoloping side effects. Read the full Novartis letter Even if this news […]

uniQure kündigt Wiederaufnahme der Patientenrekrutierung für die höhere Dosierung in der AMT-130-Studie an

A Message to the Huntington’s Disease Community from uniQure Dear Huntington’s Disease Community Members, This morning, uniQure issued a press release which included an update on our clinical trial ofAMT-130 […]

Wave Life Sciences gibt positives Update der Phase 1b/2a SELECT-HD-Studie mit ersten Ergebnissen bekannt, die auf einen allelselektiven Target-Einsatz von WVE-003 bei der Huntington-Krankheit hinweisen

September 20, 2022 at 7:30 AM EDT PDF Version Single doses of WVE-003 appear generally safe and well-tolerated CSF mutant huntingtin (mHTT) protein was reduced following single doses of 30 […]

uniQure gibt Update zur niedrig dosierten Kohorte in der klinischen Phase I/II-Studie der Gentherapie AMT-130 zur Behandlung der Huntington-Krankheit bekannt

~ Treatment generally well-tolerated with no significant safety issues related to AMT-130 in treated patients through one year of follow-up ~ ~ A mean reduction of 53.8% of mutant HTT […]

Annexon Biosciences aktualisiert Studienergebnisse

ANNEXON BIOSCIENCES REPORTS PHASE 2 CLINICAL TRIAL RESULTS DEMONSTRATING UPSTREAM CLASSICAL COMPLEMENT INHIBITION ASSOCIATED WITH CLINICAL BENEFIT IN HUNTINGTON’S DISEASE On June 7, Annexon, that is a clinical-stage biopharmaceutical company […]

Webinar - Alles, was Sie über Proof-HD wissen müssen

Gestern veranstaltete Prilenia ein Webinar zum aktuellen Stand der Phase III-Studie mit Pridopidin. Vielen Dank an alle, die teilgenommen haben, und einen besonderen Dank an unsere Referenten, Michael Hayden, Andrew Feigin, [...]

Eilmeldung - Roche plant neue Tominersen-Studie

Some encouraging news has just come in from Roche.  Analysis of the results of Roche’s Phase III GENERATION HD1 trial, which was stopped in March 2021, has found that a […]